Bristol Myers Squibb (BMY) to Release Quarterly Earnings on Thursday

Bristol Myers Squibb (NYSE:BMY) is projected to post its Q4 2025 results before the market opens on Thursday, February 5th. Analysts expect the company to announce earnings of $1.65 per share and revenue of $12.2373 billion for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 5, 2026 at 8:00 AM ET.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The business had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. During the same quarter in the prior year, the firm posted $1.80 EPS. The firm’s revenue for the quarter was up 2.8% on a year-over-year basis. On average, analysts expect Bristol Myers Squibb to post $7 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Bristol Myers Squibb Stock Down 1.6%

BMY opened at $54.66 on Thursday. The firm has a market cap of $111.26 billion, a P/E ratio of 18.46, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. The business has a 50 day moving average price of $53.07 and a 200 day moving average price of $48.55. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $63.33.

Bristol Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be given a $0.63 dividend. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.6%. The ex-dividend date of this dividend is Friday, January 2nd. Bristol Myers Squibb’s payout ratio is 85.14%.

Analysts Set New Price Targets

Several research firms recently issued reports on BMY. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Wells Fargo & Company upped their price target on shares of Bristol Myers Squibb from $53.00 to $55.00 and gave the company an “equal weight” rating in a report on Wednesday, December 10th. Guggenheim reiterated a “buy” rating on shares of Bristol Myers Squibb in a research note on Tuesday, December 23rd. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Finally, Morgan Stanley reaffirmed an “underweight” rating and issued a $37.00 target price (up previously from $36.00) on shares of Bristol Myers Squibb in a report on Friday, December 12th. Seven research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $57.43.

Hedge Funds Weigh In On Bristol Myers Squibb

Several institutional investors and hedge funds have recently added to or reduced their stakes in BMY. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. JPL Wealth Management LLC acquired a new position in Bristol Myers Squibb during the third quarter worth $36,000. Turning Point Benefit Group Inc. bought a new position in shares of Bristol Myers Squibb during the third quarter valued at $40,000. Quarry LP acquired a new stake in shares of Bristol Myers Squibb in the 3rd quarter valued at $48,000. Finally, WFA of San Diego LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth about $49,000. 76.41% of the stock is currently owned by institutional investors.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.